How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?
Yıl: 2022 Cilt: 50 Sayı: 4 Sayfa Aralığı: 237 - 238 Metin Dili: İngilizce DOI: 10.5543/tkda.2022.EE1 İndeks Tarihi: 07-07-2022
How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editoryal Erişim Türü: Erişime Açık
- 1. Turkoğlu C, Şeker T, Genc O, Yıldırım A, Topuz M. The relationship between H2FPEF score and coronary slow flow phenomenon. Turk Kard Dern Ars. 2022;50(4):242-249.
- 2. Çavuşoğlu Y, Çelik A (eds). Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches. Turk Kardiyol Dern Ars. 2022;50(Suppl 1): S1-S34.
- 3. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620. [CrossRef]
- 4. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451- 1461. [CrossRef].
- 5. https://data.tuik.gov.tr/Bulten/Index?p=Istatistiklerle-Yaslilar2021-45636.
- 6. Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-462. [CrossRef]
| APA | URAL D (2022). How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. , 237 - 238. 10.5543/tkda.2022.EE1 |
| Chicago | URAL DİLEK How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. (2022): 237 - 238. 10.5543/tkda.2022.EE1 |
| MLA | URAL DİLEK How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. , 2022, ss.237 - 238. 10.5543/tkda.2022.EE1 |
| AMA | URAL D How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. . 2022; 237 - 238. 10.5543/tkda.2022.EE1 |
| Vancouver | URAL D How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. . 2022; 237 - 238. 10.5543/tkda.2022.EE1 |
| IEEE | URAL D "How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?." , ss.237 - 238, 2022. 10.5543/tkda.2022.EE1 |
| ISNAD | URAL, DİLEK. "How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?". (2022), 237-238. https://doi.org/10.5543/tkda.2022.EE1 |
| APA | URAL D (2022). How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. Türk Kardiyoloji Derneği Arşivi, 50(4), 237 - 238. 10.5543/tkda.2022.EE1 |
| Chicago | URAL DİLEK How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. Türk Kardiyoloji Derneği Arşivi 50, no.4 (2022): 237 - 238. 10.5543/tkda.2022.EE1 |
| MLA | URAL DİLEK How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. Türk Kardiyoloji Derneği Arşivi, vol.50, no.4, 2022, ss.237 - 238. 10.5543/tkda.2022.EE1 |
| AMA | URAL D How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. Türk Kardiyoloji Derneği Arşivi. 2022; 50(4): 237 - 238. 10.5543/tkda.2022.EE1 |
| Vancouver | URAL D How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?. Türk Kardiyoloji Derneği Arşivi. 2022; 50(4): 237 - 238. 10.5543/tkda.2022.EE1 |
| IEEE | URAL D "How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?." Türk Kardiyoloji Derneği Arşivi, 50, ss.237 - 238, 2022. 10.5543/tkda.2022.EE1 |
| ISNAD | URAL, DİLEK. "How to Manage Heart Failure Patients with Not Reduced Ejection Fraction Based on Available Evidence?". Türk Kardiyoloji Derneği Arşivi 50/4 (2022), 237-238. https://doi.org/10.5543/tkda.2022.EE1 |
